US › Healthcare

Cingulate Inc (CING)

US · Healthcare · Biotechnology

$5.15+1.18%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.9M

EPS

$-0.45

EPS estimate

$-0.63

EPS came in at -0.45 against a street estimate of -0.63 — a beat of 28.6%.

Key statistics

Market cap

$73.0M

Forward P/E

0.0

P/B

3.12

Book value

$1.69

EPS (TTM)

$-3.56

52-week high

$11.89

52-week low

$3.16

50-day MA

$5.03

200-day MA

$5.31

Beta

-0.89

Analyst view

Analysts rate Cingulate Inc a buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $21.20.

Shareholding

Insiders

28.29%

Institutions

12.62%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.12%
Chicago Partners Investment Group LLC	1.30%
Kestra Advisory Services, LLC	1.04%
Geode Capital Management, LLC	0.70%
Marshall Wace Asset Management Ltd	0.64%
Jane Street Group LLC	0.62%
XTX Topco Ltd	0.37%
BCV Asset Management Inc.	0.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cingulate Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.